Clorox (NYSE:CLX) Posts Quarterly Earnings Results, Beats Expectations By $0.28 EPS

Clorox (NYSE:CLX) issued its quarterly earnings data on Thursday. The company reported $1.82 EPS for the quarter, beating the consensus estimate of $1.54 by $0.28, reports. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.97 billion. Clorox had a net margin of 3.95% and a return on equity of 382.58%. Clorox updated its FY25 guidance to $6.55-$6.80 EPS and its FY 2025 guidance to 6.550-6.800 EPS.

Clorox Trading Up 7.4 %

CLX opened at $144.07 on Friday. Clorox has a twelve month low of $114.68 and a twelve month high of $169.14. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 9.73. The company has a fifty day moving average of $133.90 and a 200-day moving average of $142.40. The stock has a market cap of $17.89 billion, a PE ratio of 74.65, a price-to-earnings-growth ratio of 1.97 and a beta of 0.39.

Clorox Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 30th. Stockholders of record on Wednesday, August 14th will be given a dividend of $1.22 per share. The ex-dividend date is Tuesday, August 13th. This is a boost from Clorox’s previous quarterly dividend of $1.20. This represents a $4.88 annualized dividend and a dividend yield of 3.39%. Clorox’s dividend payout ratio is 248.71%.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. BNP Paribas assumed coverage on shares of Clorox in a research note on Monday, June 24th. They issued an “underperform” rating and a $130.00 price objective for the company. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Clorox from $144.00 to $151.00 and gave the company a “hold” rating in a research note on Friday. DA Davidson dropped their price objective on shares of Clorox from $162.00 to $153.00 and set a “neutral” rating for the company in a research note on Friday. JPMorgan Chase & Co. dropped their price objective on shares of Clorox from $150.00 to $148.00 and set a “neutral” rating for the company in a research note on Friday. Finally, Citigroup dropped their price objective on shares of Clorox from $150.00 to $145.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. Six investment analysts have rated the stock with a sell rating and fourteen have assigned a hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $141.44.

Institutional Investors Weigh In On Clorox

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Venturi Wealth Management LLC increased its stake in Clorox by 308.5% in the first quarter. Venturi Wealth Management LLC now owns 192 shares of the company’s stock valued at $29,000 after purchasing an additional 145 shares in the last quarter. Northwest Financial Advisors bought a new stake in Clorox in the fourth quarter valued at $29,000. GoalVest Advisory LLC bought a new stake in Clorox in the first quarter valued at $31,000. First Foundation Advisors bought a new stake in Clorox in the first quarter valued at $31,000. Finally, Core Wealth Advisors Inc. bought a new stake in Clorox in the fourth quarter valued at $29,000. 78.53% of the stock is owned by institutional investors.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.